The Answer Project (TAP) is a permanently capitalized holding company that originates, develops, and commercializes deep technology IP across six domains: life sciences, artificial intelligence, semiconductors, advanced materials, quantum computing, and high-performance computing.
Most institutional capital reaches deep technology through intermediary fund structures designed around fixed timelines. Early-stage deep tech sits between the mandates of traditional venture, institutional capital, and government funding — too capital-intensive for short-cycle funds, too technical for generalist allocators, and too commercial for grants alone. TAP provides both the capital and the technical operating capability in a single vehicle, with decisions made by professionals who can evaluate the underlying science directly.
Our partnerships span national laboratories, research universities, and industry scientists — generating access to pre-commercial technology at the earliest stages of development, before conventional capital can reach it.
Deep technology requires patient capital and specialized technical judgment exercised continuously over a long time horizon. TAP is built around this reality — combining the capital, the operating capability, and the domain expertise in a single structure designed to compound value over time.
Capital markets typically price intellectual property with optimistic multiples rather than as a characterized asset. TAP adds the infrastructure to evaluate IP directly from first principles — before capital commitments scale and before conventional buyers can access it.
Each stage of development is structured to answer the highest-uncertainty questions at the lowest possible cost. This compresses the search space, allows capital to be reallocated continuously, and makes it substantially cheaper to take risks on ideas that consensus-driven processes cannot reach.
GP capital participates alongside LP capital in a single vehicle. There are no forced exits at an arbitrary fund deadline. Our incentives are structured to compound over the same long horizon as the assets we hold.
TAP operates across four focus areas, each with dedicated teams, established partnerships, and deep domain expertise. The domains are interconnected by design — materials science informs semiconductor architecture, HPC accelerates life sciences pipelines, and AI improves decision-making across every vertical. Each benefits from and contributes to a shared infrastructure and compounding knowledge platform.
Applying distributed innovation to drug discovery, biomarker development, clinical trial design, and portfolio management. We bridge academic research, biotech agility, and pharmaceutical-scale execution — with AI and empirical loops accelerating every stage.
Explore →AI is not a tool TAP uses — it is the operating system TAP is built on. Our AI-native architecture, HPC capabilities, and agentic orchestration underpin every network we form, every portfolio we manage, and every breakthrough we pursue.
Explore →Building networks across semiconductors, quantum computing, photonics, and advanced materials — the foundational layers that unlock the next generation of computing, energy, and physical technology.
Explore →Sustained outperformance requires financial and organizational innovation in lockstep with technical discovery. Our permanent capital structure and distributed risk model underpin every vertical above.
Explore →Special Assistant to the President, Biological Threats • Managing Director/Partner, BCG, PwC • Operation Warp Speed architect
Corporate and Technology Strategy • Entrepreneur, Co-Founder ValueAI Institute • Investor, Venture Partner
Senior Pharma Leadership • AI-driven Drug Discovery, Portfolio • Platform Technology and Science, GSK
Machine Learning, Deep Learning • AI Researcher/Instructor, Berkeley, NASA • Founder, Silicon Valley Bank AI Lab
Head of Operations, SaponiQx • Novavax Vaccine Lead, US Government Operation Warp Speed • Technology Selection and Clinical Evaluation, Department of Defense
Machine Learning, Computational Biology, Cancer Genomics • CSO / CTO, Cancer IQ
Quantum Computing • Senior Engineer, IonQ • Machine Learning & Physics • Financial Industry Quant
Physician Executive & Software Engineer • Chief Medical Officer, United Healthcare, VA • Faculty, Harvard Medical School • Health Tech Turnaround Leader
DNA Encoded Libraries • Informatics & Molecular Biology, Dice Therapeutics
Management Systems • High Performance Organization • Senior Lecturer, MIT Sloan
Life Sciences Strategy & Business Operations • Supply Chain, Project Management • Boston Consulting Group
Senior Pharma Leadership • Collaborative Drug Discovery, InnoCentive • R&D Executive, Eli Lilly
Professor of Neurobiology & Behavior, UC Irvine • Director, UCI Brain Initiative • Co-Founder, Augnition Labs & Enthorin Therapeutics • Memory, neuroimaging & cognitive decline • PhD, UC Irvine
TAP Neuro
Scientific Co-Founder, TAP Neuro (Alzheimer's Disease) • Professor, Harvard Medical School & MGH • Associate Member, Broad Institute of MIT & Harvard • Principal Faculty, Harvard Stem Cell Institute • Memory circuits, neurogenesis & cognitive restoration
Principal Scientist, O'Donnell Data Science & Research Computing Institute, SMU • HPC Applications Scientist, SMU • Adjunct Professor of Data Science, SMU • Computational Chemistry & Molecular Dynamics
Founder, RoutineHub • Sr TPM, WhatsApp (Meta) • Sr TPM, Amazon Alexa AI — launched first web-scale voice search engine • USC MBA
Founder, Ember Agentic Labs • Analytics & Data Science Engineering Manager, Google Cloud • Component Design Engineer, Intel • Berkeley MIDS
Kester & Byrnes Professor, Columbia Business School • Vice Dean of Research, CBS • ESG, Valuation & Corporate Governance • Schaefer Chair of Accounting, Emory University
Co-Founder & Managing Partner, Orient Growth Ventures • Co-Founder, Monitor Capital Investments & Monitor Capital Partners • LP Advisory Board, B Capital Group • Kellogg School of Management
Founder, Impact Evaluation Lab & Resolution Investors • Founder & Senior Partner, Atlas Impact Partners • Senior Portfolio Manager, AllianceBernstein • Managing Director, Nomura Securities • Executive Director, Global Macro Research, Morgan Stanley
Founder • Distributed Innovation • Entrepreneur, Impact Investor
TAP engages with partners by referral.